Huateng Pharma Provides Key Intermediate for Phase 3 Drug Candidate Aficamten
Changsha, China – September 23, 2025– Hunan Huateng Pharmaceutical Co., Ltd. today announced the supply of 1-Methyl-1H-Pyrazole-4-Carboxylic Acid (CAS 5952-92-1), a crucial intermediate in the synthesis of Aficamten (CK-274), an investigational therapy currently in Phase 3 clinical trials for the treatment of hypertrophic cardiomyopathy (HCM).
Aficamten, developed by Cytokinetics, is a next-generation cardiac myosin inhibitor designed to reduce hypercontractility of the heart muscle, a hallmark of HCM. The therapy has shown promising results in improving symptoms and cardiac function, and is now being evaluated in late-stage clinical studies.
As an established supplier of pharmaceutical intermediates, Huateng Pharma ensures high-quality, scalable, and reliable production of 1-Methyl-1H-Pyrazole-4-Carboxylic Acid to support both research and potential commercial needs.
“Our mission is to support the pharmaceutical industry from R&D through to commercialization,” said Brenda Xie, Sales Manager at Huateng Pharma. “With Aficamten advancing through Phase 3, we are ready to provide this intermediate at both pilot and large-scale production levels once the therapy reaches the market.”
Huateng Pharma continues to expand its portfolio of PEG derivatives and pharmaceutical intermediates, delivering solutions that accelerate innovation in drug development.
About Huateng Pharma
Hunan Huateng Pharmaceutical Co., Ltd. is a world-leading supplier of PEG derivatives and pharmaceutical intermediates, providing comprehensive support from lab scale to commercial production.
For inquiries, please contact:
sales@huatengusa.com
